1283 related articles for article (PubMed ID: 15893133)
1. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
2. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
[TBL] [Abstract][Full Text] [Related]
3. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
[TBL] [Abstract][Full Text] [Related]
4. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
Azuma K; Toyofuku Y; Iesaki T; Otsuka A; Tanaka A; Mita T; Hirose T; Tanaka Y; Daida H; Kawamori R; Watada H
Biochem Biophys Res Commun; 2006 Jun; 345(2):688-93. PubMed ID: 16696939
[TBL] [Abstract][Full Text] [Related]
5. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
Liebl A
Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
7. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
Delorme S; Chiasson JL
Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
[TBL] [Abstract][Full Text] [Related]
8. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
[TBL] [Abstract][Full Text] [Related]
9. Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Nakamura K; Yamagishi S; Matsui T; Inoue H
Drugs Exp Clin Res; 2005; 31(4):155-9. PubMed ID: 16223205
[TBL] [Abstract][Full Text] [Related]
10. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
[TBL] [Abstract][Full Text] [Related]
11. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
12. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Yamagishi S; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
[TBL] [Abstract][Full Text] [Related]
13. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
[TBL] [Abstract][Full Text] [Related]
14. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL
Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
[TBL] [Abstract][Full Text] [Related]
15. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose.
Frantz S; Calvillo L; Tillmanns J; Elbing I; Dienesch C; Bischoff H; Ertl G; Bauersachs J
FASEB J; 2005 Apr; 19(6):591-3. PubMed ID: 15671153
[TBL] [Abstract][Full Text] [Related]
16. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
Leschke M
Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
[TBL] [Abstract][Full Text] [Related]
17. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes.
Wagner H; Degerblad M; Thorell A; Nygren J; Ståhle A; Kuhl J; Brismar TB; Ohrvik J; Efendic S; Båvenholm PN
Diabetes Care; 2006 Jul; 29(7):1471-7. PubMed ID: 16801564
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
Hasegawa T; Yoneda M; Nakamura K; Ohnishi K; Harada H; Kyouda T; Yoshida Y; Makino I
J Gastroenterol Hepatol; 1998 Dec; 13(12):1201-6. PubMed ID: 9918426
[TBL] [Abstract][Full Text] [Related]
20. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
